Syndax Pharmaceuticals, Inc. Other Non-Current Liabilities
Syndax Pharmaceuticals, Inc. (SNDX) had Other Non-Current Liabilities of $1.00 thousand as of 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2022-03-01
- 2020-12-31: Other Liabilities, Noncurrent $1.00K.
- 2020-09-30: Other Liabilities, Noncurrent $2.00K.
- 2020-06-30: Other Liabilities, Noncurrent $3.00K.
- 2020-03-31: Other Liabilities, Noncurrent $4.00K.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2020-12-31 | $1.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $4.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $5.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $6.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $7.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $7.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $136.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $148.00K 10-Q · filed 2018-11-05 |
| 2018-06-30 | $311.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $312.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $310.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $267.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $214.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | $148.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $288.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $223.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $232.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $243.00K 10-Q · filed 2016-05-16 |
| 2015-12-31 | $70.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |